Dr. Mark Hyman warns standard labs miss early metabolic decay

Standard blood tests miss metabolic decay long before symptoms appear.

On This Week in Startups, Dr. Mark Hyman, co-founder of Function Health, argued that traditional medicine intervenes far too late because routine diagnostics skip essential biomarkers. One in three Americans delay medical visits due to cost, leaving disease to develop undetected. Function Health tests 160 biomarkers twice a year for a dollar a day - data that previously cost up to $15,000 at private concierge clinics.

"Fasting blood sugar is a lagging indicator."

- Dr. Mark Hyman, This Week in Startups

By the time fasting blood glucose rises, systemic damage has already accumulated for years. Quest Diagnostics includes fasting insulin in less than one percent of lab orders, yet 65 percent of tested Function Health members show elevated levels. Hyman explained that doctors routinely ignore insulin because mainstream pharmaceuticals do not target early metabolic dysfunction.

The rise of popular GLP-1 weight loss medications offers a quick fix for weight reduction, but Hyman cautioned against viewing them as a standalone cure. Up to 75 percent of users experience digestive side effects, while four percent suffer severe adverse events. Without heavy resistance training and high protein intake, patients lose vital muscle mass, lowering their metabolic rate and ensuring weight rebound after stopping the drug.

The misdiagnosis extends beyond metabolic health directly into mainstream psychiatry.

Hyman noted that doctors routinely prescribe SSRIs and stimulants for biological distress rooted in systemic nutritional deficits and chronic inflammation. Shortages in omega-3 fatty acids, vitamin D, and B vitamins often manifest as clinical depression or anxiety, while ultra-processed foods drive brain inflammation. In institutional trials, replacing processed foods with whole foods reduced violent incidents in juvenile detention facilities by 97 percent.

"Brain health begins in the gut and metabolic system, not in a prescription bottle."

- Dr. Mark Hyman, This Week in Startups

To bridge the diagnostic gap, large language models are now analyzing multi-omic lab panels faster than individual physicians. Hyman emphasized that AI decision support matches or exceeds doctor accuracy in standard clinical evaluations. Pairing direct-to-consumer lab access with physician-in-the-loop AI validation allows patients to catch trajectories toward diabetes or Alzheimer's years before symptoms surface.

Continuous data must replace occasional crisis management.